https://www.live-feeds.com/feed/ozempic-rival-delivers-25-weight-loss-at-highest-dose-in-phase-3-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/ozempic-rival-delivers-25-weight-loss-at-highest-dose-in-phase-3-trialhttps://www.live-feeds.com/feed/ozempic-rival-delivers-25-weight-loss-at-highest-dose-in-phase-3-trial#u106343Tue, 06 Oct 2026 12:05:55 +0000An experimental weekly injection called retatrutide achieved an average weight reduction of 25 percent among participants taking the highest dose during an 80-week Phase 3 clinical trial. Developed by Eli Lilly, the drug also demonstrated positive effects on related medical issues, including reduced knee pain and improvements in sleep apnea symptoms. Beyond retatrutide, Eli Lilly advanced other pipeline combinations such as EloraTZP, an experimental combination of eloralintide and tirzepatide that delivered greater weight loss and A1C reductions compared to tirzepatide 15 milligrams in adults